RESUMO
BACKGROUND: Atazanavir causes plasma indirect bilirubin to increase. We evaluated associations between Gilbert's polymorphism and bilirubin-related atazanavir discontinuation stratified by race/ethnicity. PATIENTS AND METHODS: Patients had initiated atazanavir/ritonavir-containing regimens at an HIV primary care clinic in the southeastern USA, and had at least 12 months of follow-up data. Metabolizer group was defined by UGT1A1 rs887829 CâT. Genome-wide genotype data were used to adjust for genetic ancestry in combined population analyses. RESULTS: Among 321 evaluable patients, 15 (4.6%) had bilirubin-related atazanavir discontinuation within 12 months. Homozygosity for rs887829 T/T was present in 28.1% of Black, 21.4% of Hispanic, and 8.6% of White patients. Among all patients the hazard ratio (HR) for bilirubin-related discontinuation with T/T versus C/C genotype was 7.3 [95% confidence interval (CI): 1.7-31.5; P=0.007]. Among 152 White patients the HR was 14.4 (95% CI: 2.6-78.7; P=0.002), but among 153 Black patients the HR was 0.8 (95% CI: 0.05-12.7; P=0.87). CONCLUSION: Among patients who initiated atazanavir/ritonavir-containing regimens, UGT1A1 slow metabolizer genotype rs887829 T/T was associated with increased bilirubin-related discontinuation of atazanavir in White but not in Black patients, this despite T/T genotype being more frequent in Black patients.
Assuntos
Sulfato de Atazanavir/efeitos adversos , Glucuronosiltransferase/genética , Infecções por HIV/tratamento farmacológico , Infecções por HIV/etnologia , Inibidores da Protease de HIV/efeitos adversos , Icterícia/etnologia , Adulto , Negro ou Afro-Americano/genética , Bilirrubina/sangue , Feminino , Estudos de Associação Genética , Genótipo , Infecções por HIV/sangue , Hispânico ou Latino/genética , Humanos , Icterícia/sangue , Icterícia/induzido quimicamente , Masculino , Pessoa de Meia-Idade , Variantes Farmacogenômicos , Polimorfismo de Nucleotídeo Único , População Branca/genéticaRESUMO
BACKGROUND: Efavirenz frequently causes central nervous system (CNS) symptoms. We evaluated genetic associations with efavirenz discontinuation for CNS symptoms within 12 months of treatment initiation. METHODS: Patients had initiated efavirenz-containing regimens at an HIV primary care clinic in the Southeastern United States and had at least 12 months of follow-up data. Polymorphisms in CYP2B6 and CYP2A6 defined efavirenz metabolizer categories. Genome-wide genotyping enabled adjustment for population stratification. RESULTS: Among 563 evaluable patients, 99 (17.5%) discontinued efavirenz within 12 months, 29 (5.1%) for CNS symptoms. The hazard ratio (HR) for efavirenz discontinuation for CNS symptoms in slow versus extensive metabolizers was 4.9 [95% confidence interval (CI): 1.9-12.4; P=0.001]. This HR in Whites was 6.5 (95% CI: 2.3-18.8; P=0.001) and 2.6 in Blacks (95% CI: 0.5-14.1; P=0.27). Considering only slow metabolizers, the HR in Whites versus Blacks was 3.1 (95% CI: 0.9-11.0; P=0.081). The positive predictive value of slow metabolizer genotypes for efavirenz discontinuation was 27% in Whites and 11% in Blacks. CONCLUSION: Slow metabolizer genotypes were associated significantly with efavirenz discontinuation for reported CNS symptoms. This association was considerably stronger in Whites than in Blacks.
Assuntos
Hidrocarboneto de Aril Hidroxilases/genética , Benzoxazinas/efeitos adversos , Doenças do Sistema Nervoso Central/induzido quimicamente , Citocromo P-450 CYP2B6/genética , Etnicidade/genética , Polimorfismo de Nucleotídeo Único , Inibidores da Transcriptase Reversa/efeitos adversos , Esteroide Hidroxilases/genética , Adulto , Alcinos , Doenças do Sistema Nervoso Central/genética , Ciclopropanos , Feminino , Predisposição Genética para Doença , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Testes Farmacogenômicos/métodos , Valor Preditivo dos Testes , Suspensão de TratamentoRESUMO
OBJECTIVE: Genome-wide association studies have identified a large number of single nucleotide polymorphisms (SNPs) associated with a wide array of cancer sites. Several of these variants demonstrate associations with multiple cancers, suggesting pleiotropic effects and shared biological mechanisms across some cancers. We hypothesised that SNPs previously associated with other cancers may additionally be associated with colorectal cancer. In a large-scale study, we examined 171 SNPs previously associated with 18 different cancers for their associations with colorectal cancer. DESIGN: We examined 13 338 colorectal cancer cases and 40 967 controls from three consortia: Population Architecture using Genomics and Epidemiology (PAGE), Genetic Epidemiology of Colorectal Cancer (GECCO), and the Colon Cancer Family Registry (CCFR). Study-specific logistic regression results, adjusted for age, sex, principal components of genetic ancestry, and/or study specific factors (as relevant) were combined using fixed-effect meta-analyses to evaluate the association between each SNP and colorectal cancer risk. A Bonferroni-corrected p value of 2.92×10(-4) was used to determine statistical significance of the associations. RESULTS: Two correlated SNPs--rs10090154 and rs4242382--in Region 1 of chromosome 8q24, a prostate cancer susceptibility region, demonstrated statistically significant associations with colorectal cancer risk. The most significant association was observed with rs4242382 (meta-analysis OR=1.12; 95% CI 1.07 to 1.18; p=1.74×10(-5)), which also demonstrated similar associations across racial/ethnic populations and anatomical sub-sites. CONCLUSIONS: This is the first study to clearly demonstrate Region 1 of chromosome 8q24 as a susceptibility locus for colorectal cancer; thus, adding colorectal cancer to the list of cancer sites linked to this particular multicancer risk region at 8q24.
Assuntos
Neoplasias Colorretais/genética , Pleiotropia Genética , Predisposição Genética para Doença , Polimorfismo de Nucleotídeo Único , Idoso , Cromossomos Humanos Par 8 , Feminino , Marcadores Genéticos , Estudo de Associação Genômica Ampla , Técnicas de Genotipagem , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Análise de Componente Principal , Sistema de Registros , Fatores de RiscoRESUMO
OBJECTIVES: Efavirenz is widely prescribed for HIV-1 infection, and CYP2B6 polymorphisms 516GâT and 983TâC define efavirenz slow metabolizer genotypes. To identify genetic predictors of higher plasma efavirenz concentrations beyond these two common functional alleles, we characterized associations with mid-dosing interval efavirenz concentrations in 84 HIV-infected adults, all carrying two copies of these major loss-of-function CYP2B6 alleles. METHODS: Study participants had been randomized to efavirenz-containing regimens in prospective clinical trials and had available plasma efavirenz assay data. Analyses focused on secondary metabolism pathway polymorphisms CYP2A6 -48TâG (rs28399433), UGT2B7 735AâG (rs28365062) and UGT2B7 802TâC (rs7439366). Exploratory analyses also considered 196 polymorphisms and 8 copy number variants in 41 drug metabolism/transport genes. Mid-dosing interval efavirenz concentrations at steady-state were obtained ≥8 h but <19 h post-dose. Linear regression was used to test for associations between polymorphisms and log-transformed efavirenz concentrations. RESULTS: Increased efavirenz concentrations were associated with CYP2A6 -48TâG in all subjects (Pâ=â3.8â×â10(-4)) and in Black subjects (Pâ=â0.027) and White subjects (Pâ=â0.0011) analysed separately; and with UGT2B7 735 G/G homozygosity in all subjects (Pâ=â0.006) and in Black subjects (Pâ=â0.046) and White subjects (Pâ=â0.062) analysed separately. In a multivariable model, CYP2A6 -48TâG and UGT2B7 735 G/G homozygosity remained significant (Pâ<â0.05 for each). No additional polymorphisms or copy number variants were significantly associated with efavirenz concentrations. CONCLUSIONS: Among individuals with a CYP2B6 slow metabolizer genotype, CYP2A6 and possibly UGT2B7 polymorphisms contribute to even higher efavirenz concentrations.
Assuntos
Benzoxazinas/sangue , Benzoxazinas/uso terapêutico , Citocromo P-450 CYP2B6/genética , Infecções por HIV/tratamento farmacológico , Metabolismo Secundário/efeitos dos fármacos , Adulto , Alcinos , Fármacos Anti-HIV/uso terapêutico , Benzoxazinas/metabolismo , População Negra/genética , Ciclopropanos , Citocromo P-450 CYP2A6/genética , Indutores do Citocromo P-450 CYP2B6/sangue , Indutores do Citocromo P-450 CYP2B6/uso terapêutico , Feminino , Dosagem de Genes , Glucuronosiltransferase/genética , Infecções por HIV/sangue , HIV-1/efeitos dos fármacos , Humanos , Masculino , Polimorfismo de Nucleotídeo Único , Estudos Prospectivos , Inibidores da Transcriptase Reversa/sangue , Inibidores da Transcriptase Reversa/uso terapêutico , População Branca/genéticaRESUMO
OBJECTIVE: In a previous analysis involving protocol ANRS 12154, interindividual variability in steady-state nevirapine clearance among HIV-infected Cambodians was partially explained by CYP2B6 516GâT (CYP2B6*6). Here, we examine whether additional genetic variants predict nevirapine clearance in this cohort. METHODS: Analyses included Phnom Penh ESTHER (Ensemble pour une Solidarité Thérapeutique Hospitalière en Réseau) cohort participants who had consented for genetic testing. All participants were receiving nevirapine plus two nucleoside analogs. The mean individual nevirapine clearance estimates were derived from a population model developed on nevirapine concentrations at 18 and 36 months of therapy. Polymorphisms were assayed in ABCB1, CYP2A6, CYP2B6, CYP2C19, CYP3A4, CYP3A5, and NR1I2. RESULTS: Of 198 assayed loci, 130 were polymorphic. Among 129 individuals with evaluable genetic data, nevirapine clearance ranged from 1.06 to 5.00 l/h in 128 individuals and was 7.81 l/h in one individual. In bivariate linear regression, CYP2B6 516GâT (CYP2B6*6) was associated with lower nevirapine clearances (P=3.5×10). In a multivariate linear regression model conditioned on CYP2B6 516GâT, independent associations were identified with CYP2B6 rs7251950, CYP2B6 rs2279343, and CYP3A4 rs2687116. The CYP3A4 association disappeared after censoring the outlier clearance value. A model that included CYP2B6 516GâT (P=1.0×10), rs7251950 (P=4.8×10), and rs2279343 (P=7.1×10) explained 11% of interindividual variability in nevirapine clearance. CONCLUSION: Among HIV-infected Cambodians, several CYP2B6 polymorphisms were associated independently with steady-state nevirapine clearance. The prediction of nevirapine clearance was improved by considering several polymorphisms in combination.
Assuntos
Fármacos Anti-HIV/farmacocinética , Povo Asiático , Variação Genética , Infecções por HIV/tratamento farmacológico , Nevirapina/farmacocinética , Adulto , Fármacos Anti-HIV/uso terapêutico , Estudos de Coortes , Feminino , Genótipo , Infecções por HIV/genética , Humanos , Modelos Lineares , Masculino , Pessoa de Meia-Idade , Nevirapina/uso terapêutico , Polimorfismo de Nucleotídeo ÚnicoRESUMO
OBJECTIVE: Tacrolimus, an immunosuppressive drug widely prescribed in kidney transplantation, requires therapeutic drug monitoring due to its marked interindividual pharmacokinetic variability and narrow therapeutic index. Previous studies have established that CYP3A5 rs776746 is associated with tacrolimus clearance, blood concentration, and dose requirement. The importance of other drug absorption, distribution, metabolism, and elimination (ADME) gene variants has not been well characterized. METHODS: We used novel DNA biobank and electronic medical record resources to identify ADME variants associated with tacrolimus dose requirement. Broad ADME genotyping was performed on 446 kidney transplant recipients, who had been dosed to a steady state with tacrolimus. The cohort was obtained from Vanderbilt's DNA biobank, BioVU, which contains linked deidentified electronic medical record data. Genotyping included Affymetrix drug-metabolizing enzymes and transporters Plus (1936 polymorphisms), custom Sequenom Massarray iPLEX Gold assay (95 polymorphisms), and ancestry-informative markers. The primary outcome was tacrolimus dose requirement defined as blood concentration to dose ratio. RESULTS: In analyses, which adjusted for race and other clinical factors, we replicated the association of tacrolimus blood concentration to dose ratio with CYP3A5 rs776746 (P=7.15×10), and identified associations with nine variants in linkage disequilibrium with rs776746, including eight CYP3A4 variants. No NR1I2 variants were significantly associated. Age, weight, and hemoglobin were also significantly associated with the outcome. In final models, rs776746 explained 39% of variability in dose requirement and 46% was explained by the model containing clinical covariates. CONCLUSION: This study highlights the utility of DNA biobanks and electronic medical records for tacrolimus pharmacogenomic research.
Assuntos
Citocromo P-450 CYP3A/genética , Registros Eletrônicos de Saúde , Imunossupressores/farmacocinética , Transplante de Rim/imunologia , Tacrolimo/farmacocinética , Subfamília B de Transportador de Cassetes de Ligação de ATP , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Adulto , Fatores Etários , Peso Corporal/genética , Bases de Dados de Ácidos Nucleicos , Relação Dose-Resposta a Droga , Monitoramento de Medicamentos , Feminino , Estudos de Associação Genética , Genótipo , Hemoglobinas/genética , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/sangue , Desequilíbrio de Ligação , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único/genética , Receptor de Pregnano X , Receptores de Esteroides/genética , Tacrolimo/administração & dosagem , Tacrolimo/sangueRESUMO
PURPOSE: Saliva is a good source of DNA for genomic research, and leukocytes are a predominant source of DNA in human saliva. Advanced human immunodeficiency virus (HIV)-type 1 infection disrupts tonsillar architecture and depletes tonsillar lymphocytes. We tested whether HIV-1 infection reduces extracted human DNA yield from saliva. METHODS: Approximately 2 mL of expectorated saliva was collected from HIV-infected adults during routine primary care clinic visits and from healthy, HIV-negative controls. Human DNA was manually extracted and was specifically quantified by assaying for the RNAse P gene. RESULTS: Seventy-five individuals were studied, including 25 HIV-infected adults with <200 CD4+ T cells/mm(3) (i.e., acquired immunodeficiency syndrome), 25 with >200 CD4+ T cells/mm3, and 25 HIV-negative controls. Overall DNA yield was 64.7 microg [29.0-139.7 microg] (median [interquartile range]). Yields were comparable among HIV-infected individuals with lower CD4+ T cell counts (74.3 microg [39.4-151.4 microg]), higher CD4+ T cell counts (63.9 microg [29.2-172.1 microg]), and HIV-negative controls (61.4 microg [28.4-123.4 microg]) (p > .05). CONCLUSION: Infection with HIV-1 does not reduce human DNA yield from saliva. Expectorated saliva should provide sufficient extracted native DNA for genomic studies in HIV-infected individuals.
Assuntos
DNA/isolamento & purificação , Infecções por HIV/genética , HIV/fisiologia , Saliva/química , Adulto , DNA/genética , Humanos , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Ribonuclease P/química , Ribonuclease P/genética , Adulto JovemRESUMO
OBJECTIVES: To compare markers of inflammation after transfusion of leukoreduced (LR) packed RBCs (pRBCs) versus non-LR pRBCs in dogs with critical illness requiring blood transfusion, and to report survival to discharge and rates of transfusion reactions in these dogs. DESIGN: Prospective randomized blinded clinical study June 2014-September 2015. SETTING: University veterinary teaching hospital. ANIMALS: Twenty-three client-owned critically ill dogs, consecutively enrolled. INTERVENTIONS: Dogs requiring a single pRBC transfusion were randomized into the LR or non-LR pRBC group. Exclusion criteria included: requirement for multiple blood products, history of previous blood transfusion, and administration of anti-inflammatory or immunosuppressive medication prior to enrollment. MEASUREMENTS: Blood samples were obtained immediately prior to transfusion, then 2 and 24 hours following transfusion. Parameters measured at each time point included: PCV, WBC count, segmented and band neutrophil counts, fibrinogen, and plasma lactate and C-reactive protein concentrations. Acute patient physiologic and laboratory evaluation fast score was calculated on admission. RESULTS: Eleven dogs were included in the LR group and 12 in the non-LR group; scores of illness severity were not significantly different between groups. Total WBC count was significantly higher in the non-LR versus LR group 24 hours following pRBC transfusion, but this difference was not evident 2 hours following transfusion. No other inflammatory parameters at any time point were significantly different between LR versus non-LR pRBC transfused dogs. Survival rates to discharge for LR and non-LR groups were 8/11 and 9/12, respectively. Acute transfusion reactions were identified in 1/11 and 2/12 dogs in the LR and non-LR group, respectively. All transfused blood was stored ≤12 days. CONCLUSIONS: Most markers of inflammation did not significantly increase following transfusion of LR versus non-LR pRBCs stored ≤12 days in ill dogs. Further prospective, randomized trials are needed in clinically ill dogs to determine the benefit of prestorage leukoreduction.
Assuntos
Preservação de Sangue/veterinária , Transfusão de Sangue/veterinária , Doenças do Cão/terapia , Inflamação/veterinária , Procedimentos de Redução de Leucócitos , Animais , Biomarcadores/sangue , Estado Terminal , Doenças do Cão/sangue , Cães , Transfusão de Eritrócitos/veterinária , Eritrócitos , Inflamação/sangue , Projetos Piloto , Distribuição Aleatória , Taxa de Sobrevida , Reação Transfusional/sangue , Reação Transfusional/veterináriaRESUMO
OBJECTIVES: Pregnancy causes a small increase in risk of venous thromboembolism (VTE), but a large increase in concern upon presentation to an emergency department (ED) with symptoms of pulmonary embolism (PE), which may cause physicians to employ a low test threshold. This was a systematic review with the hypothesis that symptomatic pregnant patients in the ED have a low relative risk (RR) for VTE outcome. METHODS: Studies in all languages were identified by structured search of PubMed, EMBASE, the Cochrane library, and bibliographies in February 2014. Papers with ED patients evaluated for possible PE that included pregnancy status, and had adequate reference standards, were included. An outcome of VTE (either deep venous thrombosis [DVT] or PE) was considered disease-positive (VTE+). Papers were assessed for selection and publication bias, and heterogeneity (I(2) ). The random effects model was used if I(2) > 24%. RESULTS: Seventeen full-length studies of 25,339 patients were analyzed. Pooled data showed I² = 0% with a symmetrical funnel plot. Two small studies with less than 1% of all patients had evidence of selection bias. The frequency of VTE+ rate among the 506 pregnant patients was 4.1% (95% confidence interval [CI] = 2.6% to 6.0%), compared with 12.4% (95% CI = 9.0% to 16.3%) among nonpregnant patients. The pooled RR of pregnancy for VTE+ diagnosis was 0.60 (95% CI = 0.41 to 0.87). Patients in the third trimester had a RR of 0.85 (95% CI = 0.40 to 1.77), and patients of childbearing age (≤45 years) had a RR of 0.56 (95% CI = 0.34 to 0.93). CONCLUSIONS: In the ED setting, physicians test for PE in pregnant patients at a low threshold, resulting in a low rate of VTE diagnosis and a RR of VTE that is lower than that for nonpregnant women of childbearing age who are tested for PE in the ED setting.
Assuntos
Complicações Cardiovasculares na Gravidez/diagnóstico , Embolia Pulmonar/diagnóstico , Trombose Venosa/diagnóstico , Adulto , Anticoagulantes/uso terapêutico , Serviço Hospitalar de Emergência , Feminino , Humanos , Gravidez , Complicações Cardiovasculares na Gravidez/prevenção & controle , Embolia Pulmonar/etiologia , Embolia Pulmonar/prevenção & controle , Risco , Medição de Risco , Trombose Venosa/complicações , Trombose Venosa/prevenção & controleRESUMO
BACKGROUND: Blood typing for the presence of Dog Erythrocyte Antigen (DEA) 1.1 is recommended in all donor and recipient dogs prior to transfusion of blood products. The objective of this study was to determine if a point-of-care DEA 1.1 blood typing cartridge could be used in place of the gel column typing method. STUDY DESIGN: Detection of DEA 1.1 was performed using a laboratory-based gel column method and a point-of-care cartridge. A convenience sample of 30 healthy blood donors, 13 dogs with immune-mediated hemolytic anemia (IMHA) (3 of which had concurrent immune-mediated thrombocytopenia [IMT]), and 44 dogs with other diseases was included in the study. KEY FINDINGS: Agreement was observed between the tests for normal dogs and dogs with nonimmune-mediated disease in 74/74 cases. Two dogs in the IMHA group had indeterminate gel column blood typing results; 1 dog in this group had a negative gel column test result but a positive cartridge test result. SIGNIFICANCE: There was good agreement between the 2 methods for normal dogs and dogs with nonimmune-mediated disease. Blood typing methods in dogs with IMHA should be further investigated.
Assuntos
Antígenos/sangue , Tipagem e Reações Cruzadas Sanguíneas/veterinária , Doenças do Cão/sangue , Cães/sangue , Sistemas Automatizados de Assistência Junto ao Leito , Anemia Hemolítica Autoimune/sangue , Anemia Hemolítica Autoimune/veterinária , Animais , Doadores de Sangue , Tipagem e Reações Cruzadas Sanguíneas/métodos , Púrpura Trombocitopênica Idiopática/sangue , Púrpura Trombocitopênica Idiopática/veterináriaRESUMO
BACKGROUND: The ADME Core Panel assays 184 variants across 34 pharmacogenes, many of which are difficult to accurately genotype with standard multiplexing methods. METHODS: We genotyped 326 frequently medicated individuals of European descent in Vanderbilt's biorepository linked to de-identified electronic medical records, BioVU, on the ADME Core Panel to assess quality and performance of the assay. We compared quality control metrics and determined the extent of direct and indirect marker overlap between the ADME Core Panel and the Illumina Omni1-Quad. RESULTS: We found the quality of the ADME Core Panel data to be high, with exceptions in select copy number variants and markers in certain genes (notably CYP2D6). Most of the common variants on the ADME panel are genotyped by the Omni1, but absent rare variants and copy number variants could not be accurately tagged by single markers. CONCLUSION: Our frequently medicated study population did not convincingly differ in allele frequency from reference populations, suggesting that heterogeneous clinical samples (with respect to medications) have similar allele frequency distributions in pharmacogenetics genes compared with reference populations.